Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Sarpatwari · SciRah

Researcher profile · Semantic Scholar

A. Sarpatwari

Share profile

A. Sarpatwari — researcher profile on SciRah

h-index: 24
Works: 158
Citations: 2,554

Most-cited papers

US public investment in development of mRNA covid-19 vaccines: retrospective cohort study
Hussain S. Lalani, Sarosh Nagar, A. Sarpatwari, Rachel E. Barenie +3 more
2023British medical journal60 citations Open access
Semantic Scholar
Assessment of Variation in State Regulation of Generic Drug and Interchangeable Biologic Substitutions.
Chana A. Sacks, Victor L. Van de Wiele, Lisa A. Fulchino, Lajja Patel +2 more
2020JAMA Internal Medicine49 citations Open access
Semantic Scholar
Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany.
V. D. Lauenroth, A. Kesselheim, A. Sarpatwari, A. Stern
2020Health Affairs47 citations
Semantic Scholar
Outcomes of the 340B Drug Pricing Program
Ryan P Knox, Junyi Wang, W. Feldman, Aaron S. Kesselheim +1 more
2023JAMA Health Forum31 citations Open access
Semantic Scholar
Barriers To US Biosimilar Market Growth: Lessons From Biosimilar Patent Litigation.
Victor L. Van de Wiele, A. Kesselheim, A. Sarpatwari
2021Health Affairs29 citations
Semantic Scholar
Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States
A. Bhasale, A. Sarpatwari, M. D. De Bruin, J. Lexchin +3 more
2020Clinical pharmacology and therapy24 citations Open access
Semantic Scholar
Use of Artificial Intelligence in Drug Development
L. Druedahl, W. N. Price, Timo Minssen, A. Sarpatwari
2024JAMA Network Open22 citations Open access
Semantic Scholar
Patent Portfolios Protecting 10 Top-Selling Prescription Drugs.
Caroline Horrow, Sarah M. E. Gabriele, S. Tu, A. Sarpatwari +1 more
2024JAMA Internal Medicine19 citations Open access
Semantic Scholar
The characteristics of patents impacting availability of biosimilars
Victor L. Van de Wiele, R. Beall, A. Kesselheim, A. Sarpatwari
2022Nature Biotechnology19 citations
Semantic Scholar
Regulatory authority and clinical acceptability: Physicians' responses to regulatory drug safety warnings
A. Bhasale, A. Sarpatwari, W. Lipworth, M. Mollebaek +4 more
2021British Journal of Clinical Pharmacology18 citations Open access
Semantic Scholar
Missed Opportunities on Emergency Remdesivir Use.
A. Sarpatwari, A. Kaltenboeck, A. Kesselheim
2020Journal of the American Medical Association (JAMA)18 citations Open access
Semantic Scholar
Frequency of First Generic Drug Approvals With "Skinny Labels" in the United States.
Bryan S Walsh, A. Sarpatwari, Benjamin N. Rome, A. Kesselheim
2021JAMA Internal Medicine17 citations Open access
Semantic Scholar
Changes in Utilization of Generic Angiotensin Receptor Blockers Following Product Recalls in the United States.
R. Desai, A. Sarpatwari, N. Gautam, J. Lii +2 more
2020Journal of the American Medical Association (JAMA)17 citations Open access
Semantic Scholar
Cost to Medicare of Delayed Adalimumab Biosimilar Availability
ChangWon C. Lee, M. Najafzadeh, Aaron S. Kesselheim, A. Sarpatwari
2021Clinical pharmacology and therapy16 citations
Semantic Scholar
Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis
Richard L. Morrow, B. Mintzes, P. Souverein, M. D. De Bruin +15 more
2022BMJ Quality & Safety15 citations Open access
Semantic Scholar
Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use
A. Sarpatwari, B. L. Brown, S. McGraw, Sara Z. Dejene +3 more
2022JAMA Network Open14 citations Open access
Semantic Scholar
A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs
A. Sarpatwari, Mayookha Mitra-Majumdar, K. Bykov, J. Avorn +12 more
2021Drug Safety14 citations
Semantic Scholar
A qualitative study of biosimilar manufacturer and regulator perceptions on intellectual property and abbreviated approval pathways
L. Druedahl, A. Almarsdóttir, S. Kälvemark Sporrong, M. D. De Bruin +5 more
2020Nature Biotechnology14 citations Open access
Semantic Scholar
Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare Savings.
Alexander C. Egilman, Victor L. Van de Wiele, Benjamin N. Rome, Jonathan J. Darrow +3 more
2022JAMA Internal Medicine13 citations
Semantic Scholar
State Laws and Generic Substitution in the Year After New Generic Competition.
Benjamin N. Rome, A. Sarpatwari, A. Kesselheim
2022Value in Health13 citations Open access
Semantic Scholar
Sponsorship and Funding for Gene Therapy Trials in the United States.
Zachary M. Kassir, A. Sarpatwari, B. Kocak, C. Kuza +1 more
2020Journal of the American Medical Association (JAMA)13 citations Open access
Semantic Scholar
Inflation Reduction Act and US drug pricing
A. Sarpatwari
2022British medical journal11 citations
Semantic Scholar
Unwanted Advice? Frequency, Characteristics, And Outcomes Of Negative Advisory Committee Votes For FDA-Approved Drugs.
C. Daval, A. Sarpatwari, A. Kesselheim
2022Health Affairs11 citations
Semantic Scholar
Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program
A. Sarpatwari, Mengdong He, Frazer A. Tessema, J. Gagne +1 more
2020Drug Safety10 citations
Semantic Scholar
Comparing Onset of Biosimilar Versus Generic Competition in the United States
R. Beall, P. Ronksley, J. Wick, Jonathan J. Darrow +2 more
2020Clinical pharmacology and therapy10 citations
Semantic Scholar
Biosimilar approval pathways: comparing the roles of five medicines regulators
Ryan P Knox, V. Desai, A. Sarpatwari
2024Journal of Law and the Biosciences9 citations Open access
Semantic Scholar
A "Method of Use" to Prevent Generic and Biosimilar Market Entry.
S. S. Tu, A. Sarpatwari
2023New England Journal of Medicine9 citations
Semantic Scholar
Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability.
R. Knox, A. Kesselheim, A. Sarpatwari
2022Journal of the American Medical Association (JAMA)9 citations
Semantic Scholar
Industry Payments to Physicians are Kickbacks. How Should Stakeholders Respond?
A. Mitchell, A. Sarpatwari, P. Bach
2022Journal of Health Politics Policy and Law9 citations Open access
Semantic Scholar
Promoting Biosimilar Competition by Revising Medicare Reimbursement Rules.
Benjamin N. Rome, A. Sarpatwari
2021JAMA Network Open9 citations Open access
Semantic Scholar
Civil commitment for opioid misuse: do short-term benefits outweigh long-term harms?
John C. Messinger, Daniel J. Ikeda, A. Sarpatwari
2021Journal of Medical Ethics9 citations
Semantic Scholar
Ensuring Safe Access to Mifepristone During the Pandemic and Beyond
B. L. Brown, S. Wood, A. Sarpatwari
2020Annals of Internal Medicine9 citations Open access
Semantic Scholar
Revisiting the National Institutes of Health Fair Pricing Condition: Promoting the Affordability of Drugs Developed With Government Support
A. Sarpatwari, Alison K LaPidus, A. Kesselheim
2020Annals of Internal Medicine9 citations
Semantic Scholar
Right to Try Requests and Oncologists' Gatekeeping Obligations.
Holly Fernandez Lynch, A. Sarpatwari, R. Vonderheide, Patricia J. Zettler
2020Journal of Clinical Oncology9 citations Open access
Semantic Scholar
State Restrictions on Mifepristone Access - The Case for Federal Preemption.
Patricia J. Zettler, A. Sarpatwari
2022New England Journal of Medicine8 citations
Semantic Scholar
High-Priced Sickle Cell Gene Therapies Threaten to Exacerbate US Health Disparities and Establish New Pricing Precedents for Molecular Medicine
Frazer A. Tessema, A. Sarpatwari, L. Rand, A. Kesselheim
2022Journal of Law, Medicine & Ethics8 citations
Semantic Scholar
Identifying potential prescription drug product hopping
Vrushab Gowda, R. Beall, A. Kesselheim, A. Sarpatwari
2021Nature Biotechnology8 citations
Semantic Scholar
Accounting for US public funding in drug development: how can we better balance access, affordability, and innovation?
A. Sarpatwari, J. Avorn, A. Kesselheim
2020British medical journal8 citations
Semantic Scholar
Removing the FDA’s Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for Ambrisentan
W. Feldman, M. Mahesri, A. Sarpatwari, K. Huybrechts +13 more
2024JAMA Network Open7 citations Open access
Semantic Scholar
Improving Drug Supply Chain Security.
Joseph T. Kannarkat, Michael W Denham, A. Sarpatwari
2024JAMA Health Forum7 citations Open access
Semantic Scholar
Diabetes Drugs: List Price Increases Were Not Always Reflected In Net Price; Impact Of Brand Competition Unclear.
A. Sarpatwari, Frazer A. Tessema, Marie Zakarian, M. Najafzadeh +1 more
2021Health Affairs7 citations
Semantic Scholar
Physician Experiences With and Perspectives on Clozapine Prescribing
A. Sarpatwari, Zhigang Lu, M. Russo, Heidi Zakoul +7 more
2025JAMA Network Open6 citations Open access
Semantic Scholar
How Do Risk Evaluation and Mitigation Strategies Impact Clinical Practice? A National Survey of Physicians
A. Sarpatwari, Zhigang Lu, Massimiliano Russo, Heidi Zakoul +8 more
2024Clinical pharmacology and therapy6 citations
Semantic Scholar
Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000–2020
M. Mahesri, A. Sarpatwari, K. Huybrechts, J. Lii +7 more
2024Drug Safety6 citations
Semantic Scholar
Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling
Bryan S Walsh, A. Kesselheim, A. Sarpatwari, Benjamin N. Rome
2022Journal of Clinical Oncology6 citations
Semantic Scholar
Improving the Use of FDA Advisory Committees.
C. Daval, A. Kesselheim, A. Sarpatwari
2022New England Journal of Medicine6 citations
Semantic Scholar
Updating the Bayh-Dole Act: March-in Rights and Transparency.
Robert Cook-Deegan, A. Kesselheim, A. Sarpatwari
2022Journal of the American Medical Association (JAMA)6 citations
Semantic Scholar
Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
S. Dusetzina, A. Sarpatwari, Michael A. Carrier, R. Hansen +2 more
2021JAMA Internal Medicine6 citations Open access
Semantic Scholar
Grounding Value‐Based Drug Pricing in Population Health
A. Kaltenboeck, Maura Calsyn, G. Frederix, Justin Lowenthal +3 more
2020Clinical pharmacology and therapy6 citations
Semantic Scholar
Patents on Risk Evaluation and Mitigation Strategies for Prescription Drugs and Generic Competition.
A. Sarpatwari, Sajeev Kohli, S. Tu, Aaron S. Kesselheim
2024Journal of the American Medical Association (JAMA)5 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Kesselheim×23
Invite
A. Kesselheim — researcher profile on SciRah
Aaron S. Kesselheim×8
Invite
Aaron S. Kesselheim — researcher profile on SciRah
Benjamin N. Rome×6
Invite
Benjamin N. Rome — researcher profile on SciRah
Gita A. Toyserkani×5
Invite
Gita A. Toyserkani — researcher profile on SciRah

Invite

G. Dal Pan — researcher profile on SciRah

Victor L. Van de Wiele×4

Invite

Su Been Lee — researcher profile on SciRah

Esther H. Zhou×4

Invite

Esther H. Zhou — researcher profile on SciRah

Invite

C. LaCivita — researcher profile on SciRah

Invite

J. Avorn — researcher profile on SciRah

Invite

W. Feldman — researcher profile on SciRah

M. D. De Bruin×3

Invite

M. D. De Bruin — researcher profile on SciRah